We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00708916
Recruitment Status : Completed
First Posted : July 3, 2008
Last Update Posted : December 11, 2012
Celgene Corporation
Information provided by (Responsible Party):
Elizabeth Camacho, New York University School of Medicine

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : August 2010
  Study Completion Date : August 2010

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 11, 2014 May 12, 2014
2 January 28, 2016 February 24, 2016
3 March 30, 2016  
4 April 25, 2016 May 31, 2016
5 June 2, 2016 July 12, 2016
6 October 18, 2016 December 9, 2016
7 July 13, 2017 August 10, 2017
8 December 27, 2017 January 23, 2018